The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada

European Respiratory Journal

Volumn 37, Issue 5, 2011, Pages 1158-1165

  Leber, A ^a   Marras, T K ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Canada; Cost effectiveness; Nontuberculous mycobacterium

Indexed keywords

AMIKACIN; AZITHROMYCIN; CARBAPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CANADA; CONTROLLED STUDY; DRUG COST; DRUG TOLERABILITY; FEMALE; HEALTH CARE COST; HUMAN; LUNG INFECTION; LUNG NONTUBERCULOUS MYCOBACTERIAL INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM XENOPEI; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; TREATMENT DURATION;

AGED; ANTI-BACTERIAL AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HUMANS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; ONTARIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES;

EID: 79955656748     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00055010     Document Type: Article

References (13)

1. Griffith DE, Aksamit T, Brown-Elliot BA, et al. An official ATS/ IDSA statement: diagnosis, treatment, and prevention of non-tuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416. (Pubitemid 46271561)
2. Huang JH, Kao PN, Adi V, et al. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999; 115: 1033-1040. (Pubitemid 29193674)
3. Marras TK, Chedore P, Ying AM, et al. Isolation prevalence of pulmonary non tuberculous mycobacteria in Ontario. Thorax 2007; 62: 661-666. (Pubitemid 47235003)
4. Ballarino GJ, Olivier KN, Claypool RJ, et al. Pulmonary non-tuberculous mycobacterial infections: Antibiotic treatment and associated costs. Respir Med 2009; 103: 1448-1455.
5. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156: S1-S19.
6. Burgos M, Gonzalez LC, Paz EA, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient approach. Clin Infect Dis 2005; 40: 968-975. (Pubitemid 40418303)
7. Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43: 451-457.
8. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 2008; 31: 596-615.
9. Stroupe KT, Teal EY, Weiner M, et al. Health care and medication costs and use among older adults with heart failure. Am J Med 2004; 116: 443-450. (Pubitemid 38388613)
10. Jenkins PA, Campbell A, Banks J, et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of mycobacterium vaccae immunotherapy. Thorax 2008; 63: 627-634. (Pubitemid 351969257)
11. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007; 101: 130-138. (Pubitemid 44835234)
12. British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 2000; 55: 210-218.
13. Miller ME, Zuckerman S, Gates M. How do Medicare physician fees compare with private payers? Health Care Financ Rev 1993; 14: 25-39.